The BAG2 Knockout HAP1 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population engineered to disrupt the BAG2 gene in the HAP1 human cell line. This polyclonal knockout pool offers a loss-of-function model for studying BAG2-mediated processes without selecting for a single clonal genotype, thereby capturing population-level variability that can be advantageous in functional genomics applications. The editing strategy employs CRISPR/Cas9 to introduce targeted gene disruption, enabling researchers to interrogate BAG2 function in a controlled cellular background.
HAP1 is a near-haploid human male cell line originally derived from a patient with chronic myeloid leukemia, displaying adherent fibroblast-like morphology and characterized by the BCR-ABL oncogenic fusion. As a leukemic cell line, HAP1 is widely employed in functional genomics and drug screening efforts due to its haploid karyotype, which simplifies genetic manipulation and loss-of-function screens. The BCR-ABL positivity and male origin further define its molecular context, making it a relevant model for studying signaling pathways intersecting with oncogenic transformation.
BAG2 functions as a co-chaperone that directly binds to the ATPase domain of HSP70, inhibiting its chaperone activity and promoting the release of client proteins. This action antagonizes CHIP-mediated ubiquitination by competing with the E3 ubiquitin ligase CHIP for HSP70 binding, thereby preventing the proteasomal degradation of substrates such as tau and p53. Through these interactions, BAG2 suppresses apoptosis and modulates protein quality control. Heat shock stress and the transcription factor HSF1 act upstream of BAG2 to regulate its expression, while downstream effects include stabilization of p53 and reduced tau clearance. The BAG2-HSP70-CHIP axis is integrated with the ubiquitin-proteasome system and apoptotic regulators like Bcl-2.
In the HAP1 leukemic background, disruption of BAG2 allows systematic investigation of how co-chaperone activity influences protein homeostasis and cell survival pathways under oncogenic stress. The BCR-ABL signaling environment provides a relevant context for assessing BAG2??s role in apoptosis regulation, potentially revealing vulnerabilities in leukemia cells. Additionally, because HAP1 cells are amenable to high-throughput genetic and pharmacological screens, this BAG2 knockout model is particularly suited for dissecting synthetic lethal interactions and identifying compounds that modulate the HSP70-CHIP-proteasome network.
These polyclonal knockout cells are suitable for western blotting, co-immunoprecipitation, ubiquitination assays, and apoptosis assays with Annexin V/7-AAD staining to assess cell death. Proteasome activity assays and immunofluorescence for protein aggregation further support protein quality control studies. Applications span functional genomics, cancer biology, neurodegenerative disease modeling, and drug screening. For further details, please contact Ascent Research.
